7 Dual agonists such as tirzepatide (GLP-1/GIP) and mazdutide (GLP-1/glucagon), as well as triple agonists like retatrutide (GLP-1/GIP/glucagon), have demonstrated unprecedented weight loss and cardiometabolic benefits in adult clinical trials
FP-A: Investigation, Conceptualization, Writing review & editing
Key Takeaways Lilly expects China could approve its oral GLP-1 obesity pill as early as 2026
Mendona L, Moura H, Chaves PC, Neves JS, Ferreira JP
Start the provider review Evidence check Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps
Each trial included at least two treatment arms/groups: one group received tirzepatide either as monotherapy or in combination with other drugs, and the other group was given a placebo or another active comparator, either alone or in combination with other drugs